Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 4/20 | 0.45 |
| ▸ | CCR8 | P51685 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117108 | 0.94 | PPARG (0.47) | PPARGPPARAFAAHCCR8KCNH2 | |
| SCHEMBL9906594 | 0.88 | FAAH (0.45) | PPARGPPARAFAAHCCR8 | |
| SCHEMBL9906620 | 0.85 | FAAH (0.45) | FAAHCCR8 | |
| SCHEMBL9906609 | 0.79 | CXCR4 (0.43) | FAAHCCR8LMNA | |
| SCHEMBL9906595 | 0.78 | FAAH (0.41) | FAAHCCR8 | |
| SCHEMBL13540691 | 0.76 | ALDH1A1 (0.47) | PPARGPPARAFAAHCCR8LMNA | |
| SCHEMBL9906612 | 0.76 | DRD2 (0.46) | FAAHCCR8LMNA | |
| SCHEMBL9906617 | 0.73 | DRD2 (0.41) | FAAHCCR8LMNA | |
| SCHEMBL9906623 | 0.73 | RAB9A (0.62) | PPARGPPARALMNA | |
| SCHEMBL13540685 | 0.71 | CXCR4 (0.52) | FAAHLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198303-B2 | Methods of use and compositions for the diagnosis and treatment of infectious diseases | SEQUELLA, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | SEQUELLA, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7652039-B2 | Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis | SEQUELLA, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20040024022-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | SEQUELLA, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | C5, THPO, TERT | PPARG 1000/4885PPARA 1528/4885FAAH 2618/4885 |
| US-20040024022-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | THPO, C5, TERT | PPARG 1159/4885PPARA 1736/4885FAAH 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.